Neuroptix Corporation


Press Releases

April 2, 2014

Cognoptix President and CEO Paul Hartung Tells Analysts: “Our Vision is to Change the Course of Alzheimer’s Disease by Enabling Early Diagnosis at the Point of Care.”

ACTON, Mass. - Cognoptix President and CEO Paul Hartung told a group of analysts yesterday: “Our vision is to change the course of Alzheimer’s disease by enabling early diagnosis at the point of care.”


Mr. Hartung made his remarks from the podium at the 9th Annual Lux Executive Summit: Seizing the Innovation Initiative, in Boston.

In February, Cognoptix announced that the strong results of a multi-site clinical trial of its SAPPHIRE II eye test, which is designed to identify Alzheimer’s disease (AD) patients via a beta-amyloid (Ab) signature in their eyes, were published in the peer-reviewed Journal of Alzheimer’s Disease & Other Dementias® (AJA).

“We have made great progress, “ Hartung added, “in developing an early-stage, non-invasive diagnostic test for AD designed to allow treatment to start before significant neuronal loss and irreversible brain damage occur.”

Mr. Hartung, who orchestrated the first-ever Series A syndicated Angel deal in the Northeast, has closed Seed, Series A, Series B and Series C rounds of financing for Cognoptix totaling $17 million with an international Angel and VC syndicate. He has extensive management experience launching successful startup businesses and leading Fortune 500 organizations. In addition to Cognoptix, Hartung has been an executive at Motorola (Winphoria Networks), 3Com Corporation, Summit Technology, Trumpf Industrial Lasers and Laser Fare, building scaleable operations, improving customer satisfaction, corporate profitability and time-to-market. He holds a Master of Science degree in Mechanical Engineering, with honors, from the Massachusetts Institute of Technology (MIT).

About Cognoptix
Cognoptix, a privately held medical technology company headquartered in Acton, Mass., is focused on developing and commercializing an in-office, drug/device diagnostic system as an aid in the early detection of Alzheimer’s Disease (AD). Its investors include Inventages Venture Capital, one of the world’s largest life sciences-, nutrition- and wellness-focused venture capital firms; Launchpad Venture Group, a Boston-based angel investment firm that provides funding to early-stage companies; and Maine Angels, accredited private equity investors in promising New England entrepreneurs and companies.

NOTE: The SAPPHIRE II system is approved for investigational use only in the United States.


#  #  #